At the start of 2026, we identified five key pharmaceutical pricing and market access trends expected to shape launch strategy, value demonstration and access planning.
At the mid-year point, these trends are moving from policy discussion into real-world implementation — with important implications for pricing strategy, global launch sequencing and HTA readiness.
US pharmaceutical pricing reform moves into implementation
Pricing reform in the United States is now entering a more operational phase.
Developments including Most Favoured Nation (MFN) pricing, the Inflation Reduction Act (IRA), and new tariff measures are increasingly influencing global pricing strategy, international reference pricing exposure and launch sequencing decisions.
Emerging markets are becoming strategic launch markets
Emerging markets such as the UAE, Brazil and China are becoming increasingly relevant in global launch strategy.
Recent approvals and regulatory developments suggest that these markets are becoming earlier launch opportunities, with drugs receiving approval sooner than historically expected. This may provide manufacturers with earlier access, regulatory validation and opportunities to generate real-world evidence, particularly as US pricing pressure increases and European healthcare budgets tighten.
EU Joint Clinical Assessment (JCA) moves into practice
The first EU Joint Clinical Assessment (JCA) has now been published, marking a key milestone in EU HTA implementation.
The focus is now shifting towards how national HTA bodies will integrate JCA outputs into local pricing and reimbursement decisions, and whether this will reduce duplication across Europe.
Public access constraints are reshaping patient access pathways
In therapy areas such as obesity, constrained public healthcare capacity is increasing the role of private and out-of-pocket access.
This trend is becoming a more visible part of the market access landscape, particularly for high-demand therapies.
New pricing and market access risks are emerging
Two additional trends are becoming increasingly relevant:
- The EU Pharma Package, which may reshape incentives, regulatory protection and launch timing
- Geopolitical disruption, which is increasingly affecting pharmaceutical supply chains, pricing and access
What this means for pricing and market access teams
The key shift in 2026 is from policy to implementation.
Pharmaceutical companies now need to assess how these developments are influencing real-world decision-making — including pricing strategy, evidence planning, launch sequencing and supply chain resilience.
Download the Mid-Year Trends Refresh of 2026 Predicted Pharma Pricing Trends
This summary highlights key developments, but the full report provides a detailed analysis of how these trends are evolving.
Frequently asked questions
What are the biggest pharmaceutical pricing trends in 2026?
- The most important pharmaceutical pricing and market access trends in 2026 relate to US price reform, global launch resequencing, evidence-driven access pressure including EU HTA implementation, public budget constraints, rising expectations for patient evidence, EU regulatory reform and geopolitical supply risk.
Has the EU JCA reduced HTA divergence?
- Time will tell. The first JCA report has been published, but its practical effect will depend on whether national HTA bodies integrate it into local processes in a consistent and meaningful way. Therefore, the impact of the JCA report on HTA divergence will not be seen until national level reimbursement is complete.
Are manufacturers changing launch sequencing strategies?
- Yes. MFN pricing, pharmaceutical tariffs, EU access reforms and emerging markets regulatory acceleration incentives and simplification are making launch order a more strategic pricing decision, particularly where international reference pricing and early value demonstration are important.
What should price and market access teams prioritise in the second half of 2026?
- Teams should stress test global price corridors, JCA evidence readiness, EU Pharma Package exposure, launch opportunities outside the EU and US, and supply chain resilience given the current geopolitical climate. Where relevant, teams should also assess private and out-of-pocket access opportunities, particularly in markets where public reimbursement may be delayed, restricted or commercially unattractive.
